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ABSTRACT
Development of a Phospholipid Encapsulation Process for Quantum Dots to be
used in Biologic Applications
Logan Michael Grimes
The American Cancer Society predicts that 1,665,540 people will be
diagnosed with cancer, and 585,720 people will die from cancer in 2014. One of
the most common types of cancer in the United States is skin cancer. Melanoma
alone is predicted to account for 10,000 of the cancer related deaths in 2014. As
a highly mobile and aggressive form of cancer, melanoma is difficult to fight once
it has metastasized through the body. Early detection in such varieties of cancer
is critical in improving survival rates in afflicted patients. Present methods of
detection rely on visual examination of suspicious regions of tissue via various
forms of biopsies. Accurate assessment of cancerous cells via this method are
subjective, and often unreliable in the early stages of cancer formation when only
few cancer cells are forming. With fewer cancer cells, it is less likely that a
cancer cell will appear in a biopsied tissue. This leads to a lower detection rate,
even when cancer is present. This lack of detection when cancer is in fact
present is referred to as a false negative. False negatives can have a highly
detrimental effect on treating the cancer as soon as possible. More accurate
methods of detecting cancer in early stages, in a nonsubjective form would
alleviate these problems. A proposed alternative to visual examination of
biopsied legions is to utilize fluorescent nanocrystalline biomarker constructs to
directly attach to the abnormal markers found on cancerous tissues.
iv

Quantum dots (QDs) are hydrophobic nanoscale crystals composed of
semiconducting materials which fluoresce when exposed to specific wavelengths
of radiation, most commonly in the form of an ultraviolet light source. The QD
constructs generated were composed of cadmium-selenium (CdSe) cores
encapsulated with zinc-sulfide (ZnS) shells. These QDs were then encapsulated
with phospholipids in an effort to create a hydrophilic particle which could interact
with polar fluids as found within the human body. The goal of this thesis is to
develop a method for the solubilization, encapsulation, and initial
functionalization of CdSe/ZnS QDs. The first stage of this thesis focused on the
generation of CdSe/ZnS QDs and the fluorescence differences between
unshelled and shelled QDs.

The second stage focused on utilizing the shelled

QDs to generate hydrophilic constructs by utilizing phospholipids to bind with the
QDs. Analysis via spectroscopy was performed in an effort to characterize the
difference in QDs both prior to and after the encapsulation process. The method
generated provides insight on fluorescence trends and the encapsulation of QDs
in polar substances. Future research focusing on the repeatability of the
process, introducing the QD constructs to a biological material, and eventual
interaction with cancer cells are the next steps in generating a new technique to
target and reveal skin cancer cells in the earliest possible stages without using a
biopsy.
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Chapter 1 – Introduction
1.1 Motivation
Cancer is the second leading cause of death in the United States,
exceeded only by heart disease (1). Cancer rates are on the rise in the United
States. According to the 2014 cancer statistics conducted by the American
Cancer Society, it is predicted that for the United States alone 1,665,540 new
cases of cancer will be diagnosed in 2014. It is also expected that 585,720 of
those in the United States who are presently living with cancer will die because of
the condition over the same year (2).Cancer can grow rapidly if left unchecked,
and can metastasize to other areas of the body (3). Cancer diagnosed at later
stages has an adverse effect on survival rate. If detection is delayed until later
stages of development, it is often too late for the patient to survive (4). One
especially common form of cancer in the United States is skin cancer. In 2014, it
is estimated that 76,100 people in the United States will be diagnosed with
melanoma alone, and nearly 10,000 will die from it. That does not include other
types of skin cancer such as basal and squamous cell carcinoma (2).
Early and accurate detection is the most reliable way to ensure a positive
outcome and the survival of a person living with cancer. By the time some
symptoms appear, the cancer may have grown and spread to a point where it is
too difficult to cure (3). As melanoma is the most aggressive type of skin cancer
it is particularly important to detect early (5). Current methods for initially
detecting cancer rely largely on visual examination, palpitation, and for some of
the most prevalent forms of cancer, routine screenings (3). If an area of tissue is
1

assessed to be at risk for having cancer, a biopsy may be performed by a
pathologist to confirm the presence of cancerous cells (6). Because this
assessment dictates a treatment plan for the patient, it is critical that the results
of the biopsy are accurate. In early stages of cancer development, detection
may prove especially difficult, and though a patient may have cancer, the testing
may miss the cancerous tissue. This leads to what is known as a false negative,
where the test states there is no problem, when in fact cancer exists. This is
likely to cause a patient to delay seeking additional medical care even if
symptoms become worse (3).
To reduce false negatives and encourage the earliest possible treatment
for cancer, it is important to design an alternative to the conventional methods of
detection, namely biopsies. A possible improvement would be to utilize
functionalized fluorescent nanocrystalline clusters of atoms known as quantum
dots (QDs) constructs. These constructs could provide a means to detect even
trace amounts of cancer that would likely be overlooked in a biopsy sample.
QDs are naturally hydrophobic, but can be functionalized to work within an
aqueous environment by utilizing amphipathic compounds such as
phospholipids. By attaching the nonpolar chains of QDs to the nonpolar chains
of the phospholipids, the QD can be surrounded by the polar heads of
phospholipids. This can allow the QDs to dissolve into a protic solvent such as
water (7). QDs are being utilized as replacements for organic fluorophores in
some biologic applications to target specified enzymes (8). Similar mechanics
could be applied to target enzymes that are associated with the initial stages of
2

cancer growth that are specific to cancerous cells in order to detect early stages
of cancer. If cancer could be detected before metastization, patient survival
would increase. Recently, many attempts have been conducted to target cancer
cells with QDs.
The purpose of this thesis is to develop a standard for the aqueous
suspension and functionalization of QDs utilizing phospholipids. The
development procedure in this thesis aimed to design constructs which could be
further processed to be utilized as a biomarker specifically for skin cancer.
Quantum dots markers could potentially be observed in the layers of the skin
without surgical intervention. Along with this, melanoma has been shown to have
false negative diagnoses. This method has the potential to replace the subjective
process of biopsies with a less subjective method for earlier detection of skin
cancer.
This introduction presents an overview of the physiology and stages of
development for cancerous cells, specifically melanoma. Along with this,
ultraviolet (UV) radiation, epidermal tissue physiology, and the effects of UV
radiation on epidermal tissue will be covered. In conjunction, the chemical
properties and biological interactions of phospholipids, and quantum behavior of
QDs will be discussed. In knowing the chemical and biological interactions of the
phospholipids, the QD construct development will have greater clarity in its
purpose. There will also be a brief summary of some of the alternative uses for
QDs in biological systems to expand upon the diverse potential applications of
QDs for medical purposes.
3

1.2 Epidermis
To understand the cancer which the QD constructs have the potential to
target, the cancer location must first be understood. The skin covers the surface
of the human body and accounts for roughly 7% of the total body weight in the
average adult. The skin serves to regulate body temperature, retain water within
the body, and to protect the body from outside pathogens and physical harm. It
has been isolated into two major layers, the vascularized deep tissue of the
dermis, and the outermost nonvascularized layer known as the epidermis (9).
Each can be divided into further sublayers. Skin cancer is most commonly
known to originate in cells of the epidermis.
The epidermis is a keratinized stratified squamous epithelium
consisting of four distinct cell types and four or five distinct layers. These cells
are dendritic cells, tactile, keratinocytes, and melanocytes. Dendritic cells, also
called Langerhans cells, ingest foreign substances, and are key activators of the
immune system. Tactile cells, also called Merkel cells, are the sensory receptors
for touch. Keratinocytes produce the fibrous protein known as keratin.
Melanocytes are the cells which synthesize the pigment melanin. Melanin which
act as a shield to protect from the damaging effects of UV radiation.
The layers of the epidermis, as seen in Figure 1, (ordered from outermost
to deepest) are the stratum corneum, stratum lucidum, stratum granulosum,
stratum spinosum, and stratum basale. The stratum corneum is a mostly
superficial layer of dead cells. The stratum lucidum is only found in areas subject
to abrasion such as the palms and soles of feet, and acts as an additional
4

protective layer. The stratum granulosum is the layer in which organelles begin
to deteriorate and fill with keratin. The stratum spinosum where cells are held in
a web-like system, and pre-keratin is formed. The deepest layer of the epidermis
is the stratum basale. In the stratum basale, a single row of stem cells
continually renew cell population, producing a variety of keratinocytes, including
melanocytes.

Figure 1: A cross sectional view of the layers of the epidermis. (10)

Depending on which skin cells mutate, and in which layer the mutation
occurs different forms of cancer occur. If mutated keratinocytes form in the
5

stratum basale, it is may become basal cell carcinoma. If it is the keratinocytes
of the stratum spinosum that are mutating, it may become squamous cell
carcinoma. If the melanocytes are mutating, melanoma may occur (9). While
cancers are often caused by mutation, a mutated cell is not necessarily
cancerous.

1.3 Cancer
Cancer refers to a wide variety of diseases characterized by the
development of abnormal cells that divide uncontrollably and may infiltrate and
destroy normal healthy tissue. Cancer has the ability to spread through the body
(11). When a cell fails to follow normal controls of cell division, and multiply to
excess, an abnormal mass of proliferating cells known as a neoplasm forms.
Neoplasms may be either benign or malignant. A benign neoplasm retains itself
in a localized area, tend to grow slowly, and seldom kill their host if removed
before they compress vital organs. In contrast cancers are malignant
neoplasms. Cancer cells invade their surroundings and may travel via blood or
lymph to other body organs where they form secondary cancer masses. This
traveling capability is known as metastasis (9).
1.3.1 Metastasis, and Risk Factors
Metastasis follows a series of stages as depicted in Figure 2. Cells grow
as a tumor. They then break through the basement membrane. This is followed
by an invasion of surrounding tissue. If the cells reach the lymphatic system or
6

blood vessels, they travel through the body. Some cells adhere themselves in
another portion of the body. At this point they spread through the wall and
proliferate to start forming a secondary tumor (12).

Figure 2: The process of metastasis. An initial mass of cancer spreads from the starting location until reaching a
body's transport system. The cancer spreads through this system starting a new tumor in a different location.(12)

There are a wide variety of factors that put individuals at risk for cancer.
Some families have a genetically heightened risk for cancer. This can be in
direct hereditary mutations that are passed from a parent to a child, or genetic
mutations that are acquired later in life (13). Roughly one in 10 patients
diagnosed with melanoma have a family member with a history of the disease.
Each person with a first-degree relative diagnosed with melanoma has a 50
percent greater chance of developing the disease than people who do not have a
family history of the disease. Individuals belonging to a melanoma family with
Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM) have a
7

heightened risk of melanoma (14). Some genetic traits even increase cancer risk
indirectly. Pale skin is known to increase the risk of developing skin cancer (5).
Along with genetic influences, the mutations which develop later in life are
often caused by environmental factors such as exposure to radiation or toxins.
The single most important risk factor for skin cancer is overexposure to UV
radiation, which damages DNA bases (9). UV radiation can come from the sun,
or man-made sources such as tanning beds and welding torches (15). UV
radiation appears to damage DNA bases, and disable tumor suppressor genes
(9). If normal genes known as proto-oncogens (genes that control how often a
cell divides) mutates, it can become a cancer-causing gene known as an
oncogene (13). Tumor suppressor genes slow cell division, repair DNA
mistakes, and cause apoptosis (programmed cell death). When these genes do
not function properly, cells may grow out of control leading to cancer. (16).
1.3.2 Methods of Skin Cancer Detection
There are methods in place to determine if an individual has skin cancer.
The most prevalent way to determine if a patient has skin cancer is to analyze a
skin lesion (abnormal area of skin) biopsy. A skin lesion biopsy is the removal of
a piece of suspected abnormal skin to diagnose or rule out an illness such as
cancer (17). There are several ways to perform a skin biopsy. There are shave
biopsies, punch biopsies, excisional biopsies, and incisional biopsies, as seen in
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Figure 3. The type of biopsy selected depends on the size, location, and type of
lesion. An excisional biopsy is usually
performed by a surgeon. The entire lesion is
removed, including beneath the skin. An
incisional biopsy, also commonly performed by
surgeons, removes a large piece of the lesion
for examination. A shave biopsy is the least
invasive method, where a small blade such as
a razor is used to remove the outermost layers
of the skin. A punch biopsy may be used for
deeper lesions. A specialized skin punch tool
is used to remove a small round piece of skin
(17). Once the biopsies are removed from the
patient, the specimen is placed in a
preservative fluid and sent to a pathology lab.
At the laboratory, a pathologist, dermatologist,

Figure 3: Various types of biopsies. (18)

or an assistant may first observe the specimen without a microscope first in a
gross examination (meaning seen without a microscope). Thereafter, or if the
specimen is too small, the specimen prepared for histological observation. The
cells are then visually observed for signs of abnormality that may indicate cancer.
Abnormal cell size or shape are indicators of cancer. If a cell’s nucleus is of
abnormal size or shape, it may be indicative of cancer as well. Malformed or
distorted glandular cells, or cell groups are also good indications that cancer is

9

present. If certain types of cells found only in specific areas of the body are
found in an unrelated area, it is likely that cancer has spread this tissue type to
the new location through metastasis (19). The most common error with a biopsy
is a false negative, which occurs when a medical professional fails to detect
cancer when a patient does have cancer (20). Some studies have seen false
negatives in as many as 16% of patients (21). A false negative can cause a
patient to ignore dangerous cancer progression for prolonged periods of time,
allowing the cancer to spread. As cancer progresses undiagnosed and untreated,
patients are more likely to die because of the cancer.
1.3.3 Cancer Markers
Cancer cells are often associated with unique markers. These markers can be
created by the cancer, or by the body in response to cancer. Most markers are
proteins, but some are genes or other substances. The markers can be found in
bodily fluids such as blood or urine, or inside of and on the tumors. While
presently tumor markers are utilized to monitor the condition of those already
diagnosed with cancer, they may hold greater potential. Many markers are
specific only to one or a few types of cancer. One example of this kind of marker
is a mutated BRAF gene. The mutated BRAF gene is an altered protein that
causes melanoma cells to grow and divide abnormally. It is found in about half of
melanomas (22). If a biomarker can be made to attach to a specific cancer
marker, then cancer markers could be utilized as part of an early detection
system. Biomarkers gathering in a specific area of the body could indicate a
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concentration of cancer markers on a tumor in the earliest stages of growth. It is
possible to attach these markers to quantum dots using phospholipids.

1.4 Quantum Dots
QDs are being designed to act as biomarkers for early, reliable,
non-subjective cancer detection. QDs are semiconductor nanocrystals that are
typically composed of a hundred to a thousand atoms (a cluster is 2-10nm in
diameter). Because of their small size, QDs maintain some characteristics of bulk
materials while also retaining characteristics of individual atoms. QDs exhibit
properties of both classical and quantum physics. This unique pairing allows a
direct influence over fluorescence characteristics by simply changing the size of
the QDs, as seen in Figure 4 (23). The distinctive electronic and fluorescent
properties of QDs can be explained by the high surface area to volume ratio as
well as a property known as quantum confinement.

Figure 4: The fluorescent wavelength of QDs vary in size. Diameter sized are given in nanometers. As size increases,
the fluorescent wavelength shifts from blue towards red.(23)

11

1.4.1Molecular Orbitals and Band Theory
Electrons exist in orbitals surrounding an atom’s nucleus. The orbitals
closest to the center of the nucleus have the lowest energy, while shells further
from the nucleus have increasingly higher energies. Electrons have a strong
tendency to occupy the lowest energy state possible, so long as no two orbitals
on the same molecule have the same energy (24). This property also extends
into bulk materials. As more atoms come into interaction with each other, orbital
energies will shift to accommodate each other. Eventually, these shifts become
so small that they can be regarded as continuous bands of energies. In bulk
semiconductors, a valence band and a conduction band form. QDs are in a
unique limbo between the atomic and bulk properties. They maintain discrete
energy levels for electrons to occupy (as in atoms), while starting to act more like
a bulk material as seen in Figure 5, and having a structure similar to bulk
materials.

Figure 5: Quantum dots hold characteristics of both atomic particles and bulk substances. They have few discrete
energy levels that exhibit band-like behavior. As size increases, more energy states become available. (25)
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The majority of electrons stay in the valence band, while few electrons move into
the conduction band (26). When electrons are stimulated with enough energy
(e.g. via the absorption of a photon), they may cross the distance between the
valence and conduction band, known as the bandgap.
1.4.2 Quantum Confinement and Bohr Exciton Radius
When electrons jump from the lower energy levels to the higher energy
levels, they leave behind a “hole”. A hole is the positively charged area left
behind when an electron transitions the bandgap from the valence to the
conduction band. The pair of an electron and the hole are known as an exciton
(27). The distance between an exciton’s electron and its hole is known as the
exciton Bohr radius. In a bulk material the exciton Bohr radius is miniscule in
comparison to the material. As the material’s size decreases to the nanoscale,
as it does with QDs, the exciton Bohr radius is constricted. The electron and the
hole are placed closer together than they would be in a bulk lattice, yielding
higher electrostatic forces between the two (28). When the material is confined
in one dimension, it creates a quantum well. Confinement in two dimensions
creates a quantum wire. Total confinement yields a quantum dot. Each of these
progressions alters the density of states in comparison to the energy as seen in

13

Figure 6. The electron energy levels move from continuous to discrete energy
states as they lose degrees of freedom.

Figure 6: As dimensions are confined, energy states become increasingly constrained. (Left to right) A bulk material (0
dimension confinement), a quantum well (1 dimension of confinement), a quantum wire (2D confinement), and a
quantum dot (3D confinement). (29)

1.4.3 Fluorescence
Once electrons are excited into the conduction band, they want to lose
energy and transition to a lower energy state, as described with the Aufbau
principle (24). When electrons relax to the ground state, the energy needs to
leave the material in a new form. This can be achieved in a combination of nonradiative decay (loss of energy through heat) and radiative decay (loss of energy
through photon emission) as seen in Figure 7 (30). While nonradiative relaxation
occurs between energy states that are close to each other, radiative decay
occurs most often in the final transition from the conduction band back down to
the ground state of the valence band. Ultraviolet light is used to excite the QD
electrons into excited states. The radiative relaxation is what causes the visible
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fluorescence of QDs. Smaller QDs will have a larger bandgap and produce light
of a higher frequency or of a shorter wavelength (31).

Figure 7: Electrons are excited by UV photons. They leave behind a hole. As the electron relaxes to the valence band
from the excited state, it releases energy in the form of nonradiative and radiative decay. A photon is released. (30)

Fluorescence can be characterized several ways. Three main factors of
fluorescence are important to potential QD biomarkers; their intensity, full width
at half maximum (FWHM), and central wavelength. Intensity is a measurement of
how many photons are being released. A brighter light will have a higher
intensity. FWHM indicates the width of a waveform at half of the maximum
intensity. A narrow FWHM in fluorescing QDs indicates similarly sized QDs. A
narrower spectrum of fluoresced light would also be more distinct and easier to
detect. Central wavelength indicates the most common wavelength of emitted
photons from the QDs. It is a good way to predict what color QDs will fluoresce.
1.4.4 Potential as a Biomarker
QDs’ distinctive fluorescence make them potentially useful as a
biomaterial. They already have been used in a broad range of biological
applications, including single molecule biophysics, optical barcoding, as well as
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molecular, cellular, and in vivo imaging. Compared to more common organic
dyes and fluorescent proteins, QDs are about 10-100 times brighter. They are
also more resistant to a phenomena known as photobleaching, the chemical
breakdown of a dye or fluorophore (8). This means that not only do the QDs
have the potential to be brighter than their organic dye and fluorophore
counterparts, they are also more resistant to breakdown in the human body.
Though they hold many advantages, the switch to the new technology will not be
without caution. QDs have several hindrances to overcome, and unknown
aspects to discover before they can be used safely within the human body.
1.4.5 Problems to Overcome with Quantum Dots as Biomarkers
The materials which compose many QDs are often harmful to the human
body. The QDs in the experiments performed were created with a cadmiumselenium core. While selenium is required by the body for proper functionality in
small amounts, in excess it is poisonous. Cadmium is a highly toxic heavy metal
and is a known carcinogen (32). Whether for benefit or hindrance, QDs may
behave differently than their bulk compounds.
One disadvantage of QDs is that they may pose a unique threat to the
human body because of their small size. The small size of the particles may
result in unusual toxicity compared to the bulk material, as well as providing new
pathways for exposure where larger particles would not go, such as through a
cell membrane (33). The particles are so small they may be able to be absorbed
into tissues and cell walls.

Chemical modifications to the surface play a large

role in QD toxicity as well. Even if the surface is processed to minimize QD
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toxicity, it is important to consider the possible effects of metal release upon QD
degradation. In vivo studies utilizing rodent models have indicated QDs may
induce inflammation and oxidative stress in some bodily systems (QD Lung
Inflammation). Studies have shown QDs elicit toxicity in a variety of in vitro
systems. The same studies indicate that the toxicity of QDs can be minimized
through selection of an appropriate shell coating, modulating surface charge,
selecting a low overall dosage, and modulating the overall QD size (7).
Another disadvantage QDs have is that their size may lead to steric
hindrance in some applications. Steric hindrance occurs when the large size of
groups within a molecule prevent reactions that are observed in related
molecules with smaller groups. QDs are larger than organic dyes that are
currently used in many imaging applications. Due to the comparative size
increase, the organic dyes may remain the superior option to QDs in some
specific imaging applications (8).
Along with this, QDs themselves are often hydrophobic particles. This
means QDs are resistant to being soluble in water. To prevent particle
aggregation, QDs are often prepared as ligands, utilizing compounds such as trin-octylphosphine oxide (TOPO) and tri-octylphosphine (TOP) to surround the QD
surface. The ligands act in such a way that the QDs do not aggregate, and
become hydrophobic. In this state, QDs are only soluble in organic solvents (34).
A representation of this can be seen in Figure 8.
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Figure 8: A quantum dot surrounded by surfactant chains to prevent coalescence of the particles.(34)

To functionalize the QDs for use as biomarkers, which can bind to
hydrophilic compounds within the body, they need to be altered. A common
method of doing this is to coat the surface of the QD with molecules that may
attach to the surface of the QD, having a have a functional group on one end and
a hydrophilic group on the other (35).

1.5 Phospholipids
To surmount some of the shortcomings of QDs, phospholipids may be
useful. Phospholipids are a class of lipids. They can be found in the lipid bilayer
of cell membranes, as well as in other natural compounds. Most phospholipids
contain a diglyceride (a hydrophobic fatty acid chain which makes the “tails”), a
phosphate group (part of the hydrophilic “head”), and a simple organic molecule
such as choline (a polar component of the “head”). Though most phospholipids
also have a glycerol backbone connecting the polar and nonpolar regions,
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Sphingomyelin is one exception to this, having sphingosine instead of glycerol. A
visual model of a typical phospholipid can be seen in Figure 9.

Figure 9: A standard phospholipid has a polar head composed of a polar group, a phosphate and (commonly) glycerol.
The nonpolar tails attached to the glycerol are found in the form of fatty acid chains. (36)

Phospholipids exhibit amphipathic character. While the “head” of a phospholipid
is hydrophilic, the “tails” of the molecule are hydrophobic. The hydrophilic head
contains a negatively biased phosphate group and may contain other polar
groups. The tail usually contains a long fatty acid hydrocarbon chain (37).
By utilizing phospholipid’s amphipathic character, the hydrophobic QDs can be
converted from hydrophobic to hydrophilic. The hydrophobic chains of the QD
have the potential to undergo interdigitation with the hydrophobic chains of the
phospholipids. By binding the compounds surrounding the QD ligands (SUCH
AS TOPO or TOP) to the phospholipid tails, the QDs become attached to the
hydrophobic tails and surrounded by the hydrophilic heads of the phospholipids.
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This creates a functionalized hydrophilic QD conjugate as represented in Figure
10.

Figure 10: The surfactant chains can bind with an external chain source such as a phospholipid to encapsulate the
particle. (34)

The two typed of phospholipids utilized in these experiments were 1,2distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-dipalmitoyl-sn-glycero3-phosphocholine (DPPC). Both are variants of phosphocholine. While the two
molecules are highly similar, DSPC has a longer “tail” chain, and therefore has a
higher molecular weight than DPPC (38).

1.6 Thesis Goal
This introductory chapter has been presented to provide the basic
technical background relevant to this thesis. Detection and diagnosis of
aggressive cancer in the earliest possible stage is critical for patient survival.
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The present methods of cancer detection, using biopsies analyzed by technicians
and doctors, are inherently subjective, have great difficulty detecting small
populations of abnormal cells, and may lead to false negatives. These false
negatives can delay diagnosis and cancer treatment, allowing cancer to grow
and spread further. This is directly detrimental to the chance of survival,
especially in aggressive cancers. A less subjective method of detecting smaller
amounts of cancer would greatly reduce false negatives. Functionalized QD
constructs are one potential tool in accomplishing this task. QD constructs have
the potential to identify trace amounts of cancer in an objective way by attaching
to cancer cells and fluorescing at specific wavelengths for easy identification.
They may have the potential to act as drug delivery devices as well.
The purpose of this thesis was to develop a foundational method for the
solublization and initial functionalization of QDs for use as biomarkers. This was
achieved through encapsulation of QDs of various emission wavelengths with a
phospholipid coating. To accomplish this, CdSe QDs were synthesized utilizing
an organometallic colloidal growth method developed at Cal Poly; this synthesis
protocol uses variation in nucleation, temperature, and times to create QDs with
the appropriate emission wavelengths. These QD cores were further coated in a
ZnS shell to improve the fluorescent properties and stability of the QDs by
reducing surface defects and broadening the potential spectrum of photons
which can excite the QD. Fluorescence measurements of intensity, full width at
half maximum (FWHM), and central wavelength were taken to observe the
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differences between unshelled QDs, shelled QDs, and QDs functionalized with
phospholipids.
These shelled quantum dots were then run through an experimentation
procedure, testing differing types of phospholipids at different concentrations.
The alteration to these concentrations and phospholipid types was meant to
discern a trend towards an ideal solubilization process. First two phospholipids
were compared to distinguish which may have had the superior solubilization of
QDs. The better of the two phospholipids was then tested at different
concentrations in an attempt to discover a trend in how to further increase the
solubility of the QDs.
The goal is to achieve a coating process for phospholipids without losing
fluorescence intensity. This thesis describes the methodology for a solubilization
and primary phospholipid functionalization of CdSe/ZnS QDs for further
development as biomarkers for skin cancer detection and treatment.
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Chapter 2 - Development and Evaluation of CdSe/ZnS Quantum Dots
2.1 Introduction
While working for IBM in 1970, physicists Dr. Leo Esaki and Dr. Raphael
Tsu were the first to produce crystalline superlattices via epitaxy of alternating
ultrathin layers, which exhibited quantum mechanical effects (39). In the same
year, IBM would be working with AT&T Bell Labs to produce two-dimensional
quantum wells. In 1983 these two-dimensional structures would further be
refined at Bell Labs into single-dimensional QDs in 1983. The term “quantum
dot” would not be coined until Mark Reed’s first lithographic QDs in 1987 (40).
This would not be the only way QDs were created.
The production of QDs can occur via multiple methods. These methods
can be easily classified into the two groups of “bottom-up” and “top-down”
synthesis. A top-down method starts with a macroscopic compound that is
reduced down to appropriate dimensions through chemical and/or mechanical
means. This process can be seen as similar to machining down a large block of
metal into a smaller useful part. While effective, the process is often tedious and
expensive (41).
The bottom-up synthesis can occur via multiple methods. These
processes include epitaxial self-assembly, colloidal synthesis, and other methods
(42). Epitaxial self-assembly begins with some form of atomic deposition onto a
semiconductor substrate. The deposited material is selected to have a smaller
bandgap than the substrate. Epitaxial “islands” spontaneously form for energetic
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reasons. These islands are made into QDs by covering them with another
semiconductor layer, having a larger band gap than the islands (43). Colloidal
synthesis does not rely on a substrate, but instead creates the QDs suspended
and dispersed through a liquid by utilizing the nucleation and growth of the QDs
in mixed precursors. These precursors contain the necessary elements (e.g.
cadmium, sulfur, or selenium) to precipitate into QDs (41). In the organometallic
precursor processes, chemicals (such as trioctylphosphane oxide) are often
added to the process to passivate the QDs. This creates crystalline
nanoparticles coated with surfactants which are highly monodisperse compared
to other methods (41). Colloidal QDs may be created through molecular
scaffold-based assembly, microbead-based assembly, arranging free QDs from a
liquid solution, and even guided self-assembly using plasma lithography. The
self-assembled or colloidal synthesized QDs are superior to the top-down
approach because of their reduced synthesis time and reduced cost in materials.
Additionally the resulting QDs are often smaller and have stronger quantum
confinement potentials than the top-down counterparts (43).
A wide variety of elements have been utilized for the synthesis of QDs.
The bottom-up methods commonly utilize elements from groups II – VI or III-V
elements (e.g. CdSe, InP for II - VI and GaN for III – V). Both the bottom-up and
top-down methods utilize group IV materials often utilizing, but not limited to
silicon (41). Of the many combinations of elements used in QD synthesis,
CdSe/ZnS core/shell QDs were among the first to be colloidally synthesized and
retain a relatively high and stable luminescence yield. Since this process’s
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development, there has been further research to replace the highly reactive
metal organic precursors. In 2000, stable ionic precursors, or “green precursors”
were introduced, greatly reducing some of the potential hazards encountered in
synthesis. By making the process safer, this shift allowed a significant growth in
the number of groups able to synthesize and investigate semiconductor
nanocrystals. The years 2002-2007 produced five times more scientific
publications on colloidal QDs than the prior twenty years combined (44). This is
evidence of the increasing interest in developing QDs for use in involved
applications.

2.2 Quantum Dot Growth
QDs can be grown by multiple methods using multiple materials. This paper will
focus on organometallic colloidal growth of CdSe QDs. In this process a
precursor solution containing selenium (Se) is created and added into another
precursor solution containing cadmium (Cd). Once the two precursors are
mixed, Se and Cd ions begin to build up until they begin to overcome the energy
barrier required for nucleation. This creates a multitude of small CdSe particles.
After an initial burst of nucleation, the newly formed QDs will then begin to grow
to larger and larger sized as the reaction continues. Extracting the QDs from this
process at different points in time should yield different sizes of QD cores,
ranging from approximately 2.7nm to 4.6nm in diameter. A representation of the
QD core formed during this process can be seen in Figure 11.
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Figure 11: A model of a CdSe QD core exhibiting the crystalline nature of the particle.(45)

2.3 Shelling Quantum Dot Cores
After creating the QD cores, the cores can be shelled with another
compound. This experiment used zinc sulfide for the shell. Because the zinc
sulfide has a larger bandgap than the core of the QD, shelling the QD cores
creates a “charge separation” in the QDs (46). The electrons want to stay in the
core of the QD, but the holes want to go to the shell. This separation changes
the properties of the QD. Of two electrons in the low energy state, one needs a
significantly larger energy increase than the other, so it typically stays at the low
level. As the other electron excites to the high-energy state and forms an
exciton, it recombines in the presence of a photon and generates two photons to
leave the material. Because of this, the fluorescence of shelled QDs should
appear brighter than unshelled QDs, even when exposed to the same energy
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(46). A shelled QD encapsulates a QD core as modeled in Figure 12. A
monolayer of ZnS is approximately .31nm (47).

Figure 12: A model of a CdSe QD core shelled in ZnS. A cutaway is shown to display the CdSe core. (45)

2.4 Process Design
Goal of the experiment is to characterize the fluorescence of unshelled
QDs over a four day span to their shelled counterparts. There was also a direct
comparison of the QDs going from their unshelled state to the shelled state.

2.5 Sample Preparation
QD cores were synthesized utilizing an organometallic colloidal growth
method. This process involves mixing two precursors, and allowing a chemical
reaction to occur for a designated period of time before the solution (now
containing QDs) is removed from the reaction vessel. Four extraction times were
used in the experiment. Extractions were taken at 0 seconds, 30 seconds, 60
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seconds, and 90 seconds. This procedure yielded four vials unshelled QDs as
seen in Figure 13.

Figure 13: Visual model of QD core synthesis process. Selenium precursor is combined with cadmium precursor at 100
degrees Celcius. Samples were extracted at 0, 30, 60, and 90 seconds.

At this point in the process, the unshelled vials were split into eight vials.
Half of the QD solutions from each vial were set aside to remain unshelled for
testing. The corresponding half of the extractions were then subjected to a
shelling procedure. The unshelled QDs were mixed with a zinc sulfide solution to
encapsulate the cadmium-selenium QDs in a zinc-sulfur shell. This process was
performed at approximately 100°C. Shelling QD samples needed to be done on
an individual, sample by sample basis. The procedure for shelling one sample of
QDs lasted 40 to 45 minutes on average, including the time required for the QDs
to cool back to room temperature. This was done twice, to two separate batches
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of QDs, creating a total of 16 samples for analysis. There were eight unshelled
samples and eight shelled samples.

2.6 Testing Samples
The area of interest in this testing was the fluorescence characteristics of
the QDs. The fluorescence characteristics measured were the intensity, the full
width at half maximum, and the central wavelength produced. The fluorescence
characteristics of these 16 samples were analyzed in two main ways.
Fluorescence characteristics of corresponding pairs of unshelled and
shelled QDs were compared (e.g. a 30-second-extraction of unshelled QDs from
Batch A compared to their 30-second-extraction shelled QDs from Batch A
counterparts). Along with the direct comparison of individual pairs, the unshelled
and shelled QDs were compared as two groups to analyze how their
fluorescence values changed over the course of four days. The fluorescence
values of these samples were measured utilizing the testing setup shown in
Figure 14.
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Figure 14: Incident light from a UV source at 385nm wavelength is directed onto QDs. A fiber optic cable at a right
angle to the incident light relays the QD fluorescence to a spectrometer. The spectrometer sends this data to a
computer for analysis.(48)

The QDs were loaded into disposable cuvettes and placed in a holding
chamber. A minimum of 2mL were used in each cuvette. In this chamber, they
were exposed to an ultraviolet beam to make them fluoresce. This fluorescence
was then conveyed down a fiber optic cable placed at 90° the incident light, to an
Ocean Optics spectrometer. This spectrometer relayed fluorescence values to a
nearby computer, where the output was measured utilizing Spectra Suite
software. In order to reduce experimental error, ten fluorescence measurements
were taken per sample per day. This allowed for analysis of the QDs to be
compared to a typical range of a day’s measurements. This would later help
indicate if changes in fluorescence values were statistically significant against the
variances of a single test. Fluorescence data was taken on Day 0 (the day the
QDs were shelled), Day 1 (the day after the QDs were shelled), and Day 3 (three
days after the QDs were shelled).
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The resultant data was then stored in a Microsoft Excel workbook. This
raw data was then processed into more useful and more easily analyzed dailyaverages. Along with the averages, standard deviations were generated so that
the measurements between days could be observed to be similar to a single
day’s measurements or not.
The unshelled to shelled assessment compared the differences in the
averages of individual unshelled samples and their shelled counterpart sample.
These differences could then be averaged themselves, revealing the average
shift of fluorescence characteristics when QDs transitioned from unshelled to
shelled state.
A simultaneous study also monitored the unshelled QD fluorescence
characteristics over the four days. Over the same timeframe, the shelled QD
fluorescence values were monitored. This data set allowed for the stability of
unshelled QD fluorescence to be compared to the stability of shelled QDs.
2.6.1 Results of Initial Change from Quantum Dot Unshelled to Shelled State
In going from their unshelled to the shelled state, QDs experienced an
increase in counts of intensity. A “count” is a measurement of intensity utilized
by Ocean Optics software. A greater intensity will have a higher count. The QDs
saw an average increase in intensity of 3407 counts after being shelled. The
population standard deviation of the unshelled and shelled intensity is roughly 71
counts. The observed increase is far outside the range of a day’s error. Further
calculations revealed this shift in intensity was a 278% increase from their
unshelled state. Measurements were taken with an integration time of 5ms. A
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paired t-test was performed on the results, showing at least 95% confidence.
The results of this can be seen in Appendix B.
The central wavelength also experienced shifts. Changes in central
wavelength were not as simple as changes in intensity. While the central
wavelength of 30 second, 60 second, and 90 second samples increased an
average of 12.3nm, the 0 second samples experienced negative shifts in
wavelength of -81nm and -109nm. The population standard deviation was
roughly 1.8nm. By excluding the more variable 0 second measurements, the
population standard deviation drops even further to 1.2nm. This calculation is
acceptable based on the fact that 0 second QD extractions were later decided to
be excluded from future production. Though there were shifts in wavelength,
they were not considered undesirable. This is because in application of a QD
biomarker, the slight shift in wavelength should not have a drastic impact. As
only the shelled QDs would be used, the average central wavelength would not
be changing unpredictably between biomarkers. The shelled QD biomarkers still
fluoresce in the spectrum of visible light.
There was also a shift in QD full width at half maximum (FWHM) going
from the unshelled to a shelled state. Once again excluding outliers of the 0
second extractions, the FWHM had an average increase of 2.66 nm. The
population standard deviation for FWHM was only 0.52 nm. This means that the
average increase in FWHM, excluding the 0 second outliers, was 6.6%. The 0
second FWHM were excluded because of the difficulty of using the software to
get an accurate FWHM. As seen in Figure 15 the FWHM is best represented in
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measuring a single peak. The multiple peaks are most prominent in the 0
second values. While multiple peaks were seen in other extraction times, there
was always a peak which overwhelmed the others in measurement. This
allowed for the other FWHMs to be more representative of the actual FWHM of
the dominant peak.

Figure 15: A representation of the full width at half max is indicated by the dashed line at the green arrow. The half
maximum is of the higher peak. This value is less representative than if there was a single peak.

2.6.2 Results of Change in Quantum Dot Fluorescence over 4 Days
There was relatively little change in either the unshelled or the shelled
QDs over the observational period of four days. The unshelled QDs experienced
no statistically significant change in central wavelength or FWHM. The average
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fluorescence values fell within one population standard deviation. The central
wavelength and FWHM remained within 1 nm of the first day’s measurement.
The average central wavelength and FWHM of shelled QDs showed no
statistically significant changes.
The only statistically significant change over the four days was the
intensity of the shelled QDs. The intensity of the shelled QDs increased an
average of another 4088 counts. The average population standard deviation of
these measurements was 90.7 counts. This translates to an additional 71%
increase in intensity compared to the initial shelling, or a 531% increase
compared to the unshelled sample counterparts.

2.7 Analysis of Fluorescence Changes
2.7.1 Analysis of Initial Change in Unshelled to Shelled State
All three fluorescence characteristics observed experienced changes
going from the unshelled to shelled state. As literature predicted, the intensity of
the fluorescence increased. This is likely due to the charge separation created
with shelling. This helped validate that the shelling procedure was effective. The
general small increase in central wavelength can be attributed to the subtle
changes in electron excitation pathways as well as the increase in QD size. The
0 second samples likely reacted differently than the other QDs because the
nucleation and growth of the QDs was in a significantly earlier stage compared to
the other QD samples. The final altered fluorescence property of FWHM did
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experience an undesirable increase. An increase in FWHM is undesirable, as it
indicates that the QDs are fluorescing a wider range of wavelengths. This would
be detrimental when trying to use them as specific optical markers. Because the
increase was small, and because the intensity increased so drastically, a shelled
QD is more desirable after the initial shelling.
2.7.2 Change Over 4 Days: Shelled
It is likely that the intensity continued to increase on average over the
course of the three days as reactants in the solution continued to slowly bond to
the QDs. Along with this, the QD structure may have reached a more stable
state. In the initial shelling process, bonds may have been imperfect and in
partially-stable bonds. These bonds had time to move to more stable states
where there was less stress on the lattice, making the QDs more uniform,
improving the shell by bonding more directly with the cores. The central
wavelength and FWHM remained statistically the same as the reactions were
small enough as to not alter the size of the QDs to where these properties would
fluctuate.
2.7.3 Change Over 4 Days: Unshelled Cores
Unlike the shelled QDs, the unshelled QDs may have experienced only
few more unshelled QDs forming and even some decomposing. The shelling
precursor already had nucleation points in the form of the QD cores, the
imperfectly-shelled QDs, and the shelled QDs. To increase intensity for
unshelled QDs, more QD cores would need to form without interfering with
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existing QDs’ absorption and emission of photons. Nucleation requires high
energy so that the Cd and Se ions can begin to bond. This was not present
when the QDs were at room temperature between tests.
2.7.4 Extractions at 0 Seconds
The 0 second extractions often acted differently than the other extraction
times. While there were only 4 samples of 0 second extractions in total, their
fluorescence characteristics were often so drastically different than the other QDs
that it warranted notice. This is because more time is needed for QD core
nucleation and growth. More time will help a uniform size of QD core to form as
the compounds begin to mix more evenly through the suspension. The 0 second
QD cores often experienced multiple similar-size peaks. This means that there
were multiple sized of QDs present. There was too much variability in
fluorescence compared to the other samples. The shelling procedure often
amplified the undesirably unique nature of the 0 second extraction fluorescence.
The 0 second extraction proved to be too unpredictable and unreliable to
produce consistent fluorescence trends.

2.8 Conclusion
This experiment provided a multitude of useful information. The 0 second
extraction will be omitted from future synthesis due to its unreliable and
unpredictable nature. While there was a slight undesirable increase in shelled
QD FWHM, it is relatively small and would not drastically affect biomarker quality.
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The shelled QDs will be used in further experimentation because of the
significantly higher intensity than the unshelled QD cores. The increased
intensity would be easier to detect either by visual observation or by a scanning
device.
No particular time interval was observed to output a specific wavelength
by any statistically valid scale. The experiment was not powerful enough to
detect differences in extraction times as there were only two samples per
extraction time of unshelled and shelled. Any observed differences could
possibly be within the scale of human error.

2.9 Additional Recommendations
If this experiment were to be repeated, it could be improved. An increase
in replicates past two batches would simultaneously improve accuracy of results
as well as allow for testing of individual time intervals. It would also be useful to
test a wider range of extraction times, as it appeared that QD cores did change in
fluorescing central wavelength as the extraction times reached greater
differences. The potentially larger QDs could react differently to the shelling
process. A wider range of time may reveal further changes to both the unshelled
and shelled QDs. The times selected would be varied based on how long the
QDs are to be kept before processing into QD constructs. This could be on the
scale of multiple weeks or months.
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Chapter 3 – Synthesis of Quantum Dot Constructs
3.1 Introduction
As discussed in section 1.4.4, QDs hold great promise as a biomarker.
Compared to most organic dyes and fluorescent proteins, QDs are brighter and
more resistant to photobleaching (8). Their tunable emission wavelength allows
for customization for multiple purposes. Multiple sizes/colors of QDs could even
be used simultaneously to identify different points of interest. They are not
without fault though. As mentioned in 1.4.5 QDs have significant problems to
overcome. The most immediate problem QDs have as biomarkers is their
hydrophobic nature. The colloidal syntheses method employed leaves the QDs
surrounded in a passivating layer TOP. While this layer is meant to prevent QD
conjugation and encourage monodispersity in the colloid, it can be utilized to
reverse the hydrophobic nature of the QD. By interdigitating the chains of a
phospholipid with the chains of the TOP coating, a QD can be turned from a
hydrophobic particle into a functional hydrophilic QD biomarker micelle (34).
Because the QD is now surrounded by the polar heads of the phospholipids, and
connected via the interdigitated chains of the phospholipid tails and TOP chains,
the QD can be immersed in water without rejection. The methods of
encapsulation were based upon previous similar processes utilized by Teresa
Pellegrino, Liberato Manna, et.al. from Ludwig Maximilians Universität München,
University of Bari, and the National Nanotechnology Lab of INFM (49). It is
hoped that the following encapsulation method will be further researched at Cal
Poly and potentially applied for use as a biotag in research.
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3.2 Preparation for Encapsulation
The synthesis and shelling of the CdSe/ZnS QDs left the QDs suspended
in octadecane (ODE). ODE, chemical formula C18H38, is a straight chain
molecule from the alkane family (50). Alkanes are insoluble in polar solvents
such as water (51). This is useful in keeping the nonpolar QDs well distributed
throughout the suspension, but is not useful in making the phospholipids soluble.
Phospholipids are highly soluble in organic solvents such as chloroform, acetone,
and benzene (52). In order to facilitate QD encapsulation with phospholipids, the
QDs needed to be suspended in such a substance. This was achieved by
precipitating the QDs out of ODE and resuspending them in chloroform. The
precipitation method utilized centrifugation of the ODE suspended QDs with an
absolute 200 proof (greater than 99.9% purity) ethanol (EtOH) mix (53). The
QDs are completely insoluble in EtOH. Due to this aspect of EtOH, and the fact
that EtOH has a higher density of 0.790 g/mL compared to ODE’s density of
0.777g/mL, EtOH acts as a useful means of separating out the QDs to create a
“pellet” of QDs at the bottom of the centrifuge tube (54). The QDs are the
heaviest substance, and are pulled to the bottom of the tube. Because the EtOH
is denser than the ODE, it is pulled below the ODE, forming 2 layers. The QDs
are then forced to mix with the EtOH, as they are the two densest substances.
This separates the QDs from the ODE.
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3.2.1 Quantum Dot Precipitation Method
Though the centrifuge could hold one to six tubes at a time, in most
instances, two tubes of equal weight were used. A portion of ODE suspended
QDs were added into each tube (e.g. 3mL of QD-ODE suspension and 6mL of
EtOH). EtOH was then added in two parts EtOH to one part QD-ODE
suspension. In the instances of uneven samples of QD-ODE suspension (where
one sample vial held more volume of QD-ODE suspension than another vial),
EtOH was added in the same 2:1 ratio for the larger sample, and EtOH was
added to the smaller sample until the mixtures were of the same volume. For
example if one sample held 2mL of QD-ODE suspension, and another vial held
3mL of QD-ODE suspension, and both were to be centrifuged simultaneously,
different amounts would be added to each. The 3mL vial would have the
standard 2:1 ratio of EtOH: QD-ODE at 6mL of EtOH added. The 2mL vial would
have 7mL of EtOH added so that both vials would hold 9mL of QD-ODE-EtOH
mixture. This was done to promote balance within the centrifuging process.
With the initial addition of EtOH, the QDs remained separated, forming
spheres of ODE-QD mix in a similar appearance to how oil separates in water.
To encourage a more even solution, EtOH was injected more forcefully into the
liquid. Once at the proper total volume, the vials were capped and then shaken
in order to agitate the solution to encourage mixing more evenly. Without this
agitation step, the surface tension of the QD-ODE solution spheres would often
remain separated, leaving the QDs suspended in ODE spheres at the base of the
vials.
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The appropriately portioned and agitated vials were then loaded into
opposite sides of the centrifuge so as to balance the machine. The vials were
spun within the centrifuge at 4000 rpm for 10 minutes, in accordance with
previous project methods. This was considered one “cycle” of centrifuging. After
one cycle, the clear supernant was removed, leaving a liquid mixture of ½ to 2
ML of QD-ODE solution. More EtOH was added in the same volume as the initial
addition. This mixture was once again agitated, and the vials were balanced. A
second cycle of 4000 rpm for 10 minutes was run. After the second cycle, if a
QD pellet had formed at the base of the vial, the EtOH and ODE were extracted
and then poured off of the QDs. On some occasions, a 3rd centrifuging cycle was
required in order to separate out the QDs well enough to remain in the vial
without being poured away with the EtOH. The samples were considered ready
for EtOH removal when the QDs had formed into a highly viscous, or solid mass
at the tip of the vial that would not flow out of the vial as the liquid was poured
away.
Once the QDs were isolated in the vial, they were placed in an active fume
hood for at least twenty-four hours so that any lingering EtOH would evaporate
out of the vials. This was the final stage of the QD isolation process. After the
drying period, the only remaining substance in the vials were the isolated QDs.
Though previous methods of QD precipitation had required occasional removal of
abnormal black precipitates, none were encountered in the trials run for this
thesis.
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3.2.2 Quantum Dot Suspension into CHCl3
Once the QDs were isolated, they needed to be resuspended into a
solvent which could both hold the non-polar QDs and dissolve the solid
phospholipid powder. Chloroform (CHCl3) served to satisfy this requirement.
Unlike the ODE, CHCl3 was able to dissolve the phospholipids as it is
significantly more polar then the ODE. It still maintained enough non-polarity to
act as a temporary solvent for the QDs without QD coalescence. CHCl3 was
added in a minimum volume of equal the original QD-ODE solution (amount of
QD-ODE added to the centrifuge vial). A greater amount of CHCl3 was often
beneficial for generating more samples for further stages in experiments.

3.3 Calculations Required for Phospholipid Encapsulation Process
To encapsulate the QDs in phospholipids, it was desirable to have a
known ratio of phospholipids to the total QD surface area in the QD- CHCl3
solution. In order to calculate this ratio, several variables needed to be analyzed
and calculated prior to phospholipid addition. The total QD surface area in the
solution was determined by utilizing the known aspects of the QD solution.
These known factors were the excitation wavelength, the weight of the QDs, and
the concentration of the QDs in the CHCl3.
3.3.1 Quantum Dot Size
One of the first variables to calculate to determine the total surface area
on the QDs in the solution was the size of an individual QD. W. William Yu, et al.
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at the University of Arkansas experimentally determined an equation to estimate
the size of a CdSe QD from the fluorescing wavelength (55). This equation is
displayed in Equation 1, where D is the average particle diameter in nanometers,
and λ is the fluorescing wavelength of the QDs.
Equation 1: Diameter=(1.61222E-9 )λ4 -(2.6575E-6 )λ3 +(1.6242E-3 )λ2 (4.277E-1 )λ+(41.57)
For example, a QD solution that emits a wavelength of roughly 549nm
should have QDs with an average diameter of 3.02 nm. The diameter can be
used to easily determine the radius of the approximately spherical QD. By
modeling the QD as a sphere, a rough estimate of the average surface area of a
QD can be calculated by utilizing the equation for the surface area of a sphere as
seen in Equation 2.
Equation 2: Surface Area=4π r 2
This gives the approximate surface area on an average-sized QD in a
solution. This is an important step in determining the total surface area available
on QDs in a QD solution. Another critical piece of information missing is the total
number of QDs in the solution. By knowing the surface area on one QD, and
knowing the approximate total number of QDs in the solution, the total surface
area available on all QDs can be determined by simply multiplying the two
values.
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3.3.2 Quantum Dot Quantity
Calculation of QD quantity starts far before the QDs are ready to be mixed
with phospholipids. In order to determine the quantity of the QDs, the average
volume of QDs must be known, as well as the total weight of the QDs. To
determine the average volume of a QD, Equation 1 can prove useful again. By
measuring the fluorescing wavelength of the QDs, the average diameter can be
calculated. The diameter indicated the radius as well. By once again modeling
the QD as a sphere, a rough estimate of the average volume of a QD can be
calculated by utilizing the equation for the volume of a sphere as seen in
Equation 3.
4
Equation 3: Volume= π r 3
3
This gives the approximate volume of an average-sized QD in the
solution. This is an important step in determining the total quantity of QDs in a
QD solution. The volume of a single QD is not useful alone. The weight of a
single QD is important.
By assuming the QD sphere model is entirely CdSe, the mass of a single
QD can be calculated. Because density is mass divided over a set volume, and
the average volume of the QD is known, by multiplying the density of CdSe by
the volume, the mass of a single QD can be determined. All that is needed after
this is to find the total weight of all of the QDs in the solution. Once the total
weight of all of the QDs is known, the approximate total number of QDs can be
44

determined by dividing the total weight of all QDs by the mass of a single QD.
The last piece missing before this calculation can be performed is the total weight
of all of the QDs. This can’t be determined by the fluorescence, or by simplifying
the model. It must be measured.
Measurement of total QD weight is most easily performed before and after
the centrifuging process. To find the total weight of QDs in the centrifuging vial, it
is simpler to measure the change in the centrifuge vial’s weight with the QDs
within, rather than to try and remove, weigh, and replace the QD pellet. To do
this, the empty vials must be weighed before any QD solution is added. It was
also important to keep the caps of vials matched with the vials so that any minor
differences in cap weight did not skew the weight of the vials before and after
QDs were isolated inside of them.
The process for weighing out the QDs was simple. The empty centrifuge
vial would be weighed and the value recorded. The QD-ODE solution would be
added, and centrifuged in the process described in section 3.2.1. Once the vials
were dry, with the QD pellet inside, they were weighed once again. The initial
weight of the empty vial would be subtracted from this new weight of the vial with
the QDs within. The resulting difference would be the approximate mass of all of
the QDs in the vial. This was considered to be the total weight of all QDs. While
the concentration of QDs would change, the total weight of the QDs would not.
Once the weight of all QDs was determined, along with the approximate
average weight of a single QD, the total quantity of QDs in the vial was simple.
By dividing the total weight of the QDs by the weight of a single QD, the number
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of QDs could be calculated. Due to the incredibly small size of the QDs, it was
not abnormal to have estimates in the hundreds of quadrillions, or X.XXXe17.
Significant figures were observed, making the estimates roughly accurate down
to the 1014 scale (e.g. 665,700,000,000,000,000).
3.3.3 Quantum Dot Concentration and Total Surface Area
Once an approximation of the total number of QDs had been determined,
then the QD concentration can be determined. Previous procedures added the
same quantity of CHCl3 as the ODE (56). By regarding the ODE solution as the
set minimum, the QDs would have a highly similar concentration to when they
first formed. This may be regarded as desirable as it is how the QDs
spontaneously formed without being overly concentrated in the solution. While
this was regarded as the minimum amounts, it often roved beneficial to have a
larger quantity of solution, even at the cost of a reduced concentration. By
increasing the total number of samples which could be generated by each vial of
QDs, the variable of “QD size” could be essentially eliminated. Vials were filled
to the 10mL mark near the top of the vial. This was roughly 3-5mL more CHCl3
than the previous fluid of ODE. The diluting of the QDs from the previous ODEQD concentration would not be a significant problem as the specific
concentration of QDs in the solution needed to be calculated regardless. No
value of QD concentration in the ODE-QD solution had been calculated before
this step, so resuspending the QDs in the same volume of CHCl3 as ODE would
not be important.
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To calculate the concentration of QDs, first a set amount of CHCl3 needed
to be added. Once the QDs were suspended in a set volume of CHCl3, the
concentration could be calculated by dividing the total number of QDs by the total
volume of the CHCl3-QD solution. This solution could then be divided into
several samples for further testing of phospholipid encapsulating.
3.3.4 Phospholipids per Square Nanometer of Quantum Dot Surface Calculation
There were two main variable factors in determining the amount of
phospholipids to add to each sample. These variables were the type of
phospholipid added and the desired number of phospholipids to cover each QD
surface. Each hold a major factor in determining the weight of phospholipid
powder to add into the solution.
As the phospholipids were in a powder form, and not in solution, the best
way to quantify how many phospholipids were being added was to utilize the
molecular weight of an individual phospholipid molecule. The molecular weight
of the phospholipid indicates the weight of a single phospholipid molecule. This
can be utilized to calculate approximately how many molecules are in a given
mass of phospholipid powder. One experimental variable was the type of
phospholipid being used. As the differing phospholipids had distinct molecular
weights, a different weight of phospholipid powder would need to be added to a
sample to achieve the same concentration of phospholipids per square
nanometer of QD surface.
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Another experimental factor which was tested was the desired number of
phospholipids to add per square nanometer of QD surface. To vary this factor,
the concentration of phospholipids added to the concentration of QDs needed to
be considered. A higher concentration of phospholipids compared to the QDs in
the solution would theoretically provide more phospholipids to attach to each
individual QD. A lower concentration would similarly have fewer phospholipids to
attach to each QD. By varying the concentration of phospholipids added to the
solution, the amount of phospholipids per surface was altered. Because the size
of a sample was controlled, and the concentration and size of the QDs within the
sample were already set, the simplest way to alter the concentration of
phospholipids compared to the QDs was to alter the amount of phospholipids
being added to a sample. To do this, different quantities of phospholipids would
need to be added. This was quantified by adding different weights of
phospholipid powder. Once again, the quantity of phospholipid molecules added
could be determined by using the molecular weight for each type of phospholipid.
The final equation for determining how much phospholipid powder to add
took the form of Equation 4, where NA is Avogadro’s number. The experimental
factors altered in testing have been bolded.
Equation 4:
Weight of Phospholipids to Add= Total Surface Area of QDs in Sample ×
Desired Number of Lipids per nm2 QD Surface Area÷
NA ×Molecular Weight of Phospholipid
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The “Total Surface Area of QDs in Sample” was measured in “nm 2”, the
“Desired Number of Lipids per square nanometer of QD Surface Area” was
measured in “1/nm2”, by dividing by NA the units were the same as multiplying by
“mol”, and finally the molecular weight was measured in “g/mol”. These units
reduce to result in a mass in grams to add to the sample.

3.4 Phospholipid Encapsulation Process
Once the calculations have yielded the amount of a specific phospholipid
to add to a sample of CHCl3-QD solution, the encapsulation process can be
performed. There are three major steps in the encapsulation process: the
weighing and addition of the phospholipids to the sample, a rotovaping
procedure, and resuspension in water with buffer.
3.4.1 Weighing and Addition of Phospholipids
The phospholipid powder was stored in a freezer so as to preserve the
phospholipids from breaking down. Once the appropriate weight of powder had
been calculated for a sample, the phospholipids were measured out on a scale
as accurately as possible. The powder was then transferred into an empty round
bottom flask. The transfer was best accomplished by utilizing an inert paper.
The paper was folded in half diagonally before being placed on the scale. The
scale was then set to zero with the paper on it to compensate for the new weight.
The phospholipids were then spooned onto the paper utilizing a stainless steel
chemistry spatula. Once at the appropriate amount, the whole paper containing
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the phospholipids could be lifted from the scale. The paper could then be twisted
into a funnel shape so that as much of the phospholipids as possible could be
knocked into the flask without spilling. After the phospholipids were in the flask,
the predetermined amount of CHCl3-QD mix (as used to calculate the quantity of
phospholipids needed) was added into the flask. The flask was then closed and
agitated to encourage an initial mixing of the solution to become more evenly
dispersed. Just shaking the flask was not adequate though.
3.4.2 Rotary Evaporation
After the CHCl3-QD-phospholipid sample had been prepared, it was
moved to a rotary evaporation machine similar to the one pictured in Figure 16.
The round bottom flask acted as the “pot” in the figure. The flask was locked into
place with a clip before a vacuum was placed onto the system, sealing it shut. A
motor was then turned on to rotate the flask. This rotation kept the mixture
constantly agitated so that no moisture would be trapped beneath a layer. The
final evaporated substance would form a thin film on the internal walls of the
flask, rather than accumulating only at the base. The vacuum encouraged rapid
evaporation of the CHCl3 as well. This even and rapid evaporation was desirable
so that the QD-phospholipid constructs (QDCs) could form throughout the
mixture, in a timely manner, with as little CHCl3 left in the substance as possible.
The formation of QDCs was further promoted during the resuspension into a
polar substance.
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Figure 16: A schematic of a typical rotary evaporation machine. The QDs in the "pot" rotate in a water bath while a
vacuum is induced on the interior to accelerate evaporation. (57)

3.4.3 Resuspension in Water and Buffer
After evaporation, the QDCs (and remaining bare QDs and unattached
phospholipids) were ready for resuspension into a protic solvent. The solvent
chosen was a mixture of water with a tris-borate buffer (0.5 x Tris-Borate-EDTA
(TBE, Sigma-Aldrich #T-3912)). This buffer would act to further solubilize the
remaining phospholipids so that they would better attach to the remaining bare
QDs. For consistency, 3mL of this buffer solution was added to every
evaporated QDC sample. This final suspension was then capped and agitated
via shaking before being immersed into a sonicator for 30 minutes. The
sonicator acted to further agitate the samples, dispersing the nanoparticles in the
liquid, promoting more exposed QD surfaces for which the loose phospholipids
could adhere. After this final stage, the QDC suspension was taken in for
spectral characterization.
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3.5 Experimental Procedure Variations for Quantum Dot Encapsulation
Though Section 3.4 states the procedure of how to perform the process, it
does not indicate the specific factors altered and tested through the experiments
performed, nor the testing methods utilized. Both full samples, and partial
samples were tested in an effort to observe different characteristics of the
solutions. Two types of phospholipids were tested, one factor at a time altered, it
does not indicate the specific alterations that occurred throughout the
experimentation. The main variables were the type of phospholipid used and the
desired phospholipid concentration per square nanometer.
3.5.1 The Two Sample Extraction Types
There were multiple variations of extractions performed on the samples for
testing. A “full-sample” method and a “partial-sample” method were both utilized.
A full-sample extraction transferred the entire contents of a given flask of QDs
which had gone through the encapsulation process, and loaded these contents
into a cuvette for testing. The full-sample testing accounted for observing all
components of the given solution. A partial-sample selectively removed a set
amount (2mL) of the solution from the top of the solution downwards, removing
the uppermost portion of the sample within the flask. This was done in an
attempt to extract only the suspended particles in the top layer of the solution.
Each method yielded unique results.
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3.5.2 The Two Phospholipid Types
The two phospholipid types used were both variants of phosphocholine.
One type was DPPC, and the other was DSPC. Though they had almost
identical chemical composition, but the chains composing the phospholipid “tails”
were of different lengths. This caused them to be different molecular weights.
Because DSPC has longer carbon chain tails, it had a higher molecular weight
(790 g/mol) than DPPC (734 g/mol) (38). A model of these chains can be seen
in Figure 17, with DPPC (molecular formula C40H80NO8P) on the left, and DSPC
(molecular formula C44H88NO8P) on the right.

Figure 17: Two variations of the phosphocholine phospholipid. (Left) DPPC has a shorter tail chain length than DSPC
(right). (38)

The first variable selected for testing was the type of phospholipid to be
used. It was selected as the first variable due to available quantities of
phospholipids, and reducing the total number of tests. By testing the two types
first, less total samples needed to be prepared, which saved time, QDs,
phospholipids, and by extension money. There was also the added benefit of
being able to use one specific size of QD for testing both types of phospholipids.
Limiting the samples to one average size of QD eliminated variability between
tests.
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The first experiments compared a control group of QDs without
phospholipids, QDs with DSPC at a concentration of three phospholipids per
square nanometer, and QDs with DPPC at a concentration of three
phospholipids per square nanometer. By keeping the concentration set at three
phospholipids per square nanometer, any differences between measured values
would be isolated to the difference in the phospholipids. Trials were run for each,
and it was decided that the smaller DPPC was the superior phospholipid for the
process. The reasoning for this and results of the experiments will be discussed
in Chapter 4.
3.5.2 Altering the Concentrations of DPPC
The first trial of DPPC tested the phospholipids at a concentration of three
phospholipids per square nanometer. This trial remained useful to compare to
the experiments of the DPPC-specific tests. The second set of experiments
focused on varying the concentrations of DPPC. Two new concentrations were
selected to test both greater and lesser concentrations of phospholipids. If
fluorescent properties proved better by either increasing or decreasing the
concentration, then further experiments could be directed towards increasing or
decreasing the quantity of phospholipids. The two new concentrations selected
were ten phospholipids per square nanometer, and one phospholipid per square
nanometer. Along with these two concentrations, a second control of purely
DPPC was generated, using the equivalent amount of phospholipids as would be
used for a concentration of ten phospholipids per square nanometer of QD
surface.
54

3.6 Fluorescence Characterization
The QDC suspension fluorescence was measured utilizing the same
process documented in section 2.7. The fluorescence values observed were
compared to the corresponding values of the QDCs in their QD-ODE stage. The
QD- CHCl3 stage had been shown to have nearly identical fluorescence to the
QD-ODE stage. The comparison of fluorescence was used to identify major
differences in fluorescence peaks’ locations, differences in fluorescence intensity,
and any new fluorescence patterns to the QDC suspension.
Samples were scanned utilizing a ten scans-to-average output in order to
reduce instantaneous variability. This means that the sample was averaged over
ten scans to create a single graphical output. These averaged scans were
measured every 5 seconds over the course of 6 minutes, creating 72 readings of
the spectrum. These outputs were then averaged to provide the average
fluorescence over the 6 minute span.
To compare the phospholipids, two samples were generated, comparing
DSPC and DPPC with QDs, both having a ratio of three phospholipids per
square nanometer of QD surface. Once the superior phospholipid (DPPC) was
selected (why it is superior in section 3.7.1), the concentration of phospholipids
per square nanometer was varied using only the superior phospholipid. The new
concentrations to be tested against the three phospholipid per square nanometer
were one phospholipid per square nanometer, and ten phospholipids per square
nanometer. These samples were also compared a control group of pure QDs,
and a control group of pure phospholipids (having the same quantity of
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phospholipids as the ten phospholipids per square nanometer of QD surface
sample). Each comparison yielded unique insights. An ideal QDC would have a
distinct emission from the QDs, and a high signal to noise ratio at that emission.
Reflected light would be minimized, and the QD fluorescence would be
maximized.

3.7 Results
There were two areas of interest in the observed spectrum of light. The
first area about the excitation wavelength (390nm) indicated how much of the
excitation wavelength was being observed within the sample. This wavelength
was created by the excitation source of a UV laser. A lower intensity is desirable
in this area. A lower intensity indicates a larger absorbance of UV light by the
quantum dots. Less UV light would also be useful in application with biomarkers,
as there would be less interference when trying to locate the QDs of another
wavelength. The second area of interest was the wavelengths surrounding the
QD fluorescence. A greater intensity in this area indicates a greater amount of
QDs fluorescing. When in solution, a higher intensity of QD fluorescence can
indicate a larger amount of QDs within a solution. An ideal sample would have a
low UV intensity, but a high QD fluorescence.
3.7.1 DSPC vs DPPC Fluorescence
The first set of experiments compared DPPC and DSPC phospholipids to
a control group of pure QDs that had gone through the same coating process
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without any phospholipids present in the procedure. Both the DPPC and DSPC
phospholipids were utilized in concentrations of three phospholipids per square
nanometer of QD surface.
The first sample type measured was the full sample. The UV spectrum
seen in Figure 18. In the UV wavelength, the QD control appeared to have a
higher intensity than either of the QD samples processed with DSPC or DPPC.
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Figure 18: Full sample measurement in the UV excitation spectrum of QDs processed with DSPC and DPPC
phosphocholine phospholipids compared to a QD control group processed with no phospholipids.

The QD fluorescence spectrum of the two phospholipid type tests is seen in
Figure 19. In this full sampling method, there is an undesirable signal to noise
ratio. It is difficult to distinguish any meaningful information from the graph.
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While it appears as though the DPPC phospholipid sample may have had the
highest intensity, it is not highly distinguishable from the other samples.
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Figure 19: Full sample measurement in the QD Fluorescent spectrum of QDs processed with DSPC and DPPC
phosphocholine phospholipids compared to a QD control group processed with no phospholipids. A poor signal to
noise ratio is seen.

In an attempt to reduce the variability of the sample, a partial sampling
method was then utilized. This process attempted to extract only QDs which
were suspended in the uppermost layer of the sample. The result of the partial
sample in the QD spectrum is seen in Figure 20.
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Figure 20: Partial sample measurement in the QD fluorescence spectrum of QDs processed with DSPC and DPPC
phosphocholine phospholipids compared to a QD control group processed with no phospholipids. The samle processed
with DSPC shows no fluorescence.

The partial sample revealed data following a clearer pattern, with a far better
signal to noise ratio, with more distinguishable features for each sample. The
QD control appeared to have some QD fluorescence, but the DSPC had no
noticeable QD fluorescence. The sample with the highest fluorescence was the
sample utilizing the DPPC phospholipids. In the ultraviolet spectrum, the partial
sample yielded different results than the full sample. As seen in Figure 21, the
DSPC sample had the lowest UV excitation peak, while DPPC sample had the
greatest peak, even above the QD control. While a low UV peak is desirable, it
was deemed more important to have a higher fluorescence. A biomarker that did
not fluoresce would not be useful. The DPPC phospholipids with QDs were
selected as the more desirable pairing. The DPPC phospholipids were used for
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further experimentation.
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Figure 21: Partial sample measurement in the UV excitation spectrum of QDs processed with DSPC and DPPC
phosphocholine phospholipids compared to a QD control group processed with no phospholipids.

3.7.2 The Altered Concentration of DPPC
The altered concentrations added in a new control group of phospholipids
suspended without QDs. The new concentrations of one phospholipid per
square nanometer, and ten phospholipids per square nanometer were then
compared to the previous concentration of three phospholipids per square
nanometer, and the phospholipids without QDs control. The phospholipid control
was at the same concentration of phospholipids as the ten phospholipids per
square nanometer sample.

60

The full sample was observed first. In the ultraviolet range, there were
distinct differences between the peaks of the phospholipid control, the three
phospholipid per square nanometer concentration, and the one and ten
phospholipid per square nanometer concentrations. As seen in Figure 22, the
highest UV intensity was the phospholipid control. While the one and ten
phospholipid concentrations appeared similarly low, the three phospholipid
concentration was between the sets in intensity.
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Figure 22: Full sample measurement in the UV excitation spectrum of QDs processed with various concentrations of
DPPC phosphocholine phospholipids (per nm square) compared to a DPPC control group processed with no QDs.

The full sample of the QD fluorescence wavelength showed a poor signal to
noise ratio once again. There was a noticeable difference between the control
group of only phospholipids and the phospholipids processed with the QDs. As
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seen in Figure 23, it is difficult to distinguish a difference between the different
concentrations, but the control group is different than any of the other samples.
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Figure 23: Full sample measurement in the QD fluorescence spectrum of QDs processed with various concentrations of
DPPC phosphocholine phospholipids (per nm square) compared to a DPPC control group processed with no QDs. The
control shows little to no fluorescence

Once again, a partial sampling method was utilized in an attempt to
discover potential differences between the concentrations. The partial sampling
method revealed distinguishable differences between some samples. The ten
phospholipid concentration had a greater intensity than either of the other
phospholipid with quantum dot concentrations. All samples processed with QDs
had a greater intensity than the phospholipid only control. This can be seen in
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Figure 24.
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Figure 24: Partial sample measurement in the QD fluorescence spectrum of QDs processed with various concentrations
of DPPC phosphocholine phospholipids (per nm square) compared to a DPPC control group processed with no QDs.

Unlinke in the tests comparing the two different phospholipids, UV spectrums of
the partial and full testings were highly similar. As seen in Figure 25, the
phospholipid control maintains the greatest UV intensity, with the three
phospholipid concentration lower, and the one and ten phospholipid
concentrations at the lowest UV intensity.
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Figure 25: The partial sample values of the UV fluorescence spectrum for altering concentrations of DPPC with QDS
compared to a pure DPPC control.
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Chapter 4 – Discussion and Conclusions
The experiments performed revealed interesting trends and results. Due
to the lack of repetitions in these experiments, a statistical validity cannot be
assigned to the observations.

4.1 Chloroform/ODE Suspension vs Aqueous Quantum Dots
Before observing the experimental results, it was important to consider the
desired outcomes. When the QDs were suspended in ODE, they had an
intensity of roughly 10,000 counts of intensity around the QD fluorescence
wavelength. This remained the same when resuspending in CHCl3 Along with
this, there was no noticeable UV excitation peak present. This indicates that the
QDs were well suspended throughout the solution, both absorbing the UV
excitation wavelength of light, and fluorescing. The high intensity of fluorescence
(compared to the experimental results) indicates a high number of quantum dots
suspended in the solution (compared to the experimental results). If the QDs
were suspended as well in the new aqueous solution, the intensities would be
proportionate. As the QDs were diluted in the aqueous solution to a 0.3
concentration compared to the CHCl3, a desirable resuspension intensity would
be approximately 3,000 counts. The QD control group in the aqueous solution
showed an intensity of 100 counts, indicating the QDs were not in solution as
well. The highest intensity of any processing method was only 484 counts (peak
of full sample, ten phospholipid concentration). While this was an improvement
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over the control group, it remained substantially lower than the desired intensity
of 3,000 counts. This indicates that the encapsulation process was not as
effective as desired.

4.2 Full Samples vs. Partial Samples
Full samples were used as the initial measurements. They showed
distinct differences compared to the partial samples. The full samples displayed
a wider range of intensities for fluorescence. The signal to noise ratio was
noticeably poor at the QD fluorescence wavelength spectrum, and it was difficult
to distinguish meaningful trends from in most cases. It did however have a
constant greater intensity at the QD fluorescence wavelength spectrum for all
samples. This was likely due to there being more QDs throughout the sample.
The partial samples were meant to isolate only the QDs suspended in the
aqueous solution, removing any variability introduced from particles that were not
well suspended in the solution. It was used as a crude purification process to
separate the soluble QDs from the insoluble QDs. The partial samples had a
better signal to noise ratio, with a predictable and clear trend in their graphs.
They did have a lower intensity than their full sample counterparts. This is likely
due to the reduction in QDs available within the sample. With fewer QDs, the QD
fluorescence will be less intense. The partial samples also ran the risk of being a
poor representation of the processing method as a whole. It is possible that
more or fewer QDs were extracted from the sample by chance during the
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extraction process. This was not a risk in the full samples as all of the sample
was transferred.

4.2 The Superiority of DPPC Phosphocholine Phospholipids
The DPPC phosphocholine phospholipids appeared to be the superior of
the two phospholipids tested. Though the DPPC and DSPC phospholipids
appeared similar in the full sample testing, It appeared as though the higher
intensities were being reached by the DPPC, while the DSPC had a slightly lower
intensity (-50 to -150 counts) overall. The partial sample testing method revealed
more obvious differences between the samples. The partial DSPC sample
showed no intensity of light within QD fluorescence spectrum. The DPPC
showed an increased intensity of fluorescence, greater than that of the QD
control group or DSPC. In application this means that the QDCs utilizing DSPC
would not be distinguishable from any other substance. Though the UV
excitation wavelength in the partial sample with DPPC was nearly three times the
intensity of the sample using DSPC, DPPC was still superior. This is because
the QD fluorescence was clearly apparent. Not only was it apparent, it was
greater than the QD control, indicating that more QDs (or QDCs) were in
suspension in the aqueous substance. Because the DPPC tests showed that the
QDCs with DPPC had a higher fluorescence at the QD fluorescence, they were
considered to be the superior choice for further experimentation despite the fact
that they had a higher UV excitation peak in the partial sample.
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One potential cause of the poor performance of the DSPC phospholipids
was the longer tail chain length compared to the DPPC counterparts. The longer
chains would allow more flexibility and movement of the polar heads of the
phospholipids. This would cause more interactions between the polar heads of
the phospholipids. With more interactions, and more repulsion between the
similarly charged heads, steric hindrance could occur. This would prevent more
phospholipids from attaching to the QD surface. In contrast, the shorter chains of
the DPPC would have been less free in their movement on the surface of the QD
as their short tails would impede how far the polar heads could move. This
would allow more phospholipids to attach with less interaction between the polar
heads of the phospholipids. This in turn would cause the QD surface to have
greater encapsulation in a polar phospholipid head covering. With a more polar
encapsulation of individual QDs, QDs would be more readily suspended in an
aqueous solution. A representation of this can be seen in Figure 26
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Figure 26: The longer tail chains of DSPC (left) allow for more movement of the polar head of the phospholipid. This
may cause more interference between phospholipids when compared to DPPC (right), where the shorter tails restrict
movement of the polar heads. (58)

. It is also worth noting that the hydrocarbon chains (tails) of the DPPC
are more similar in length to those of the TOP surfactant chains than the DSPC
tails. The tail of the DPPC phospholipid has a shorter length than the tail of the
DSPC phospholipid. As the agent surrounding the QDs when they are created in
ODE is TOP, the chain length of the TOP would hold a large influence on how
the QD was coated further. TOP’s chemical equation is P(C8H17)3. As the DPPC
carbon chain (C40H80) is shorter than DSPC (C44H88), it is of a more similar length
to TOP than DSPC. As the chain lengths are more similar, the DPPC may be
more likely to bond to the TOP compared to the DSPC.
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It seemed uncharacteristic that the DSPC would have a lower QD
fluorescence in the aqueous solution than the QD control. This could have been
caused by chance in a single run of the experiment. Further iterations of the
experiment may reveal the partial suspension of QDs in the aqueous solution as
abnormal.

4.3 The Ten Phospholipids per Square Nanometer of Quantum Dot Surface
Concentration
Of the three concentrations tested (one DPPC phospholipid per square
nanometer of QD, three DPPC phospholipids per square nanometer, and ten
DPPC phospholipids per square nanometer), the ten-phospholipid concentration
appeared to have the most desirable fluorescence. While this was not especially
clear in the full sample, the partial sample revealed that the ten phospholipid
concentration appeared to have more QDs suspended in the aqueous solution.
The one and three phospholipid concentrations were of similar, lower intensities
compared to the ten phospholipid sample. The highest intensity fluorescing
sample in the QD spectrum was the ten phospholipid per square nanometer of
QD surface concentration.
When observing the UV peaks, a lower intensity is desirable to reduce
interference when attempting to detect the QDCs. The worst performing of the
QD with DPPC samples in both the full and partial sampling methods was the
three-phospholipid concentration. While it had a lower UV peak than the DPPC-
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only control group, had a higher intensity than either of the other two samples.
While the one-phospholipid concentration was the lowest in the partial sampling
method, it was slightly higher than the ten-phospholipid concentration in the full
sample. In both instances, the intensities appeared similar. Because the
samples are so similar, it is worth contrasting the UV peak intensity against the
QD fluorescence intensity. In the partial samples, the ten-phospholipid
concentration sample had a QD fluorescence of 41.6% intensity compared to the
UV peak. The one-phospholipid concentration had a QD fluorescence intensity
of 31.4% of its UV peak. Not only was the overall QD fluorescence intensity of
the ten-phospholipid sample greater than the one-phospholipid counterpart, it
had a greater ratio of QD fluorescence to UV interference.
The ten DPPC phospholipids per square nanometer concentration
seemed to have the most desirable fluorescence. It exhibited the greatest UV
fluorescence of all of the samples, as well as the greatest fluorescence in
comparison to UV interference.
In the partial samples, there were risks in misrepresenting the whole
sample. If the partial sample acted as a reliable, if crude, purification method
which was representative of the whole sample, the ten phospholipid
concentration was the most desirable of the samples. Further repetitions of the
experiment would be useful to determine this. If several repetitions of the full
samples were run, the sample values could be averaged, and a trend line fitted
to the data. This trend line would more reliably represent the specific
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concentration, and reduce variability. These values could be cross referenced
against the trends observed in the partial sample method.

4.4 Three-DPPC per Quantum Dot Surface Fluorescence
Though the three-DPPC per square nanometer did prove effective in
increasing QD fluorescence compared to the control, it had a larger UV excitation
peak than either the one or ten-phospholipid concentration samples. This does
not follow a trend relating phospholipid concentration to UV excitation observed.
It is possible that the altered concentrations were not well represented in the
testing as the phospholipids were not likely to completely dissolve in the pure
CHCl3.

4.5 Areas for Improvement within Current Methods
There are many aspects of the present methods which would benefit from
improvement. Some improvements may not be easily feasible, if at all possible,
while others could be done soon. Increasing the number of repetitions on each
experiment would reduce potential experimental error, environmental effects, and
overall variability. Many of the improvements involve the accuracy of estimating
the size of QDs and the corresponding amount of phospholipids.
The calculation for determining the diameter of a QD based on fluorescent
wavelength was meant for uncoated CdSe QDs. While the wavelength did shift
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once the QDs were shelled with ZnS, there was not a particular discernable
pattern to the shift, nor could it be assumed that the shift would perfectly coincide
with what the shift would indicate if the QDs were purely CdSe. The mass of the
QDs were similarly regarded as purely CdSe. While it is true that the core, and
the majority of the mass is CdSe, it is not in fact pure CdSe. This minor
difference was likely overshadowed by the weighing procedures. Small
discrepancies in any scale measurement results in major shifts in the number of
QDs estimated. Because there are so many QDs, these shifts may not have a
major difference in the end result so long as they are kept to a minimum.
The calculation for the phospholipid concentration was also based only the
peak’s central wavelength. In reality, the QDs were not of one perfectly uniform
size, but instead a narrow spectrum of slightly differing sizes. It was assumed
that the different sizes were an approximately normal distribution, so the smaller
sized QDs would roughly balance with the larger sized QDs when the
phospholipid concentration was added.
In the encapsulation procedure, two major changes could benefit the
interaction of QDs binding with phospholipids. Changing the resuspension
process in resuspending the QDs from ODE into CHCl3 utilizing a cosolvent
along with ethanol could prove a more reliable resuspension method. Along with
this altered process, the resuspension solution needs to be altered. Methanol
can be mixed with chloroform to allow for the phospholipids to dissolve more
easily in the solution. Though this may alter the QD dissolving in the solution,
improved dissolving of phospholipids is desirable.
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4.6 Future Work
Because the shorter chained DPPC appeared to perform better than the
DSPC counterpart, it could prove useful to test even shorter chain lengths of
phospholipids. As mentioned before, it is important to change the solution into
which the phospholipids are being mixed with the QDs in order to promote equal
dissolving regardless of the specific phospholipid used.
A more direct method of characterization would be significantly useful in
determining if deductions about QD coatings are accurate or reliable. This does
not need to be done via imaging. A titration process could be used on the
unprocessed QDs and compared to the processed QDs. If the phospholipids
have bonded with the surfactant chains the surface charge of the interacting
bodies will change. With the change in the surface charge, the pH of the solution
would be altered as well.
There is great potential for future work once an encapsulation procedure
has been established. The final aqueous suspension of QDs could be introduced
into biological media, such as keratinocyte skin cells, to observe the interaction
with cellular tissue, especially potential movement through a cell wall. Beyond
this, the QDs could be further functionalized to interact with specific biological
markers, such as the markers specific to skin cancer.
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4.7 Conclusion
Though there are many potential methods for solubilization and
phospholipid functionalization of QDs for use in a hydrophilic medium such as
biologic tissue, this thesis refines the previous attempts made at Cal Poly, and
introduces new methods. This method continues to hold great potential for
cellular tagging, both for cancer cells in the future, as well as for experiments
performed at Cal Poly’s facility presently. Further characterization and process
optimization would be useful before proceeding to those steps. This work has
great potential to have an impact on future work at Cal Poly, and beyond.
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Appendix A1: “SMALL BATCH” CdSe SYNTHESIS PROCEDURE WITH
SILICONE OIL BATH FOR HEATING
The following CdSe/ZnS synthesis protocol and analysis procedure are the
standard protocol and procedure documented by Josh Angell and used by Cal
Poly’s Biomedical Department.

The first part of this procedure outlines 3 different techniques (Purging,
Syringing, & Oil Bath Operation) which are required for quantum dot synthesis.
The second part contains instructions to create the selenium/cadmium
precursors and then react them to synthesize CdSe quantum dots.

Chemicals
 13 mg Cadmium Oxide Powder
 33 mg Selenium Powder
 0.6 mL Oleic Acid (tech grade 90%)
 15 mL Octadecene (tech grade 90%)
 0.4 mL Trioctylphosphine (tech grade 90%)
 Toluene and Acetone for cleanup
Equipment
 2 – 50mL 14/20 1-neck or 3-neck Round Bottom Flasks
 2 – 1mL Disposable Plastic Syringes
 2 – 3mL Disposable Plastic Syringes
 1 – 5cc Glass Syringe, Luer Lock Tip
 1 – Veterinary Tip, 18 gauge, 3” SS Needle
 2 – Small Stir Bars
 3 to 5 – 7.5 mL Borosilicate Vials
 1 – Medium-Sized Beaker (150 mL)
 2 to 4 – Rubber Septa
 Hot/Stir Plate with RTD Probe
 Crystallization Dish
 ~ 200 mL – High Temperature Silicone Oil
 Chemical Spatula
 Kimwipes
 Thermocouple
 Analytical Balance
 Stopwatch
 Latex or Nitrile Gloves
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Chemical Disposal
All chemicals and equipment used during the quantum dot synthesis must be
properly disposed of. Currently there is a vessel for liquid waste and a
container for solid wastes such as needles, syringes, kimwipes, etc. which are
stored in the yellow, hazardous chemical cabinet in the nanotech lab (Bldg. 41205).

Preparing Chemical Bottles
1. Fill a clean dry bottle with the
desired chemical.
2. Fit a rubber septum into the top of
the bottle.
3. Either purge the solution if it is to
be used immediately or store it for
later use.
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Purging Procedure
This procedure is to be used for any chemical and/or reaction vessel needing
purging.
1. Fill a large beaker with water until it
is ¾ full.
2. Lower N2 tank gas escape hose
into beaker.

3. Fully open valve on top of tank.
4. Fully open left knob on valve.
5. Open middle knob on valve
(“increase”) until bubbles start to
appear in the beaker. Maintain this
gas flow throughout the procedure.
6. Insert N2 purge needle into center
of septum. Make sure the needle is
above the level of the liquid.
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7. Insert a vent needle into the
septum next to the N2 purge
needle. Make sure it is above the
level of the liquid.

8. After inserting the vent needle,
lower the purge needle so that the
tip is submerged in the liquid.
Bubbles should begin to
form in the liquid. If the needle
cannot be submerged below the
level of the liquid, either more
chemical can be added or the bottle
can be carefully tilted.
9. Allow to bubble for at least 10
minutes to remove oxygen from the
chemical.
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Syringing Procedure
This procedure is a method of transferring a chemical from one purged vessel
into another without the introduction of oxygen. All solutions must be properly
purged with N2 before using this procedure.
1. Remove a disposable plastic
syringe from its packaging.

2. Pull the N2 purge needle up so that
it is above the level of the liquid. No
bubbles should be forming at this
point.
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3. Insert the tip of the syringe into
the venting needle.
4. Draw N2 gas up into the syringe.

5. Remove the N2 filled needle and
syringe from the septum and fully
expel all the N2 gas by plunging the
syringe down. Make sure to expel
the syringe away from yourself in
the hood.
6. Reinsert the needle and syringe
into the septum.
7. Repeat the filling and expelling
process twice more. This removes
any oxygen in the syringe.
8. Reinsert the needle and syringe
then pull up the syringe to once
again fill the syringe with N2. Do not
remove the syringe from the flask.
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9. Fully pull out the N2 purge
needle.

10. Plunge down the N2 filled
syringe to create positive pressure
in the vessel.
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11. Invert the chemical vessel and
syringe.
12. Slowly draw out the desired
amount of solution into the syringe.
Make sure to keep the needle tip in
the liquid to prevent gas from
entering the syringe.

13. Quickly and carefully insert the
needle into the center of the septum
of the desired vessel and slowly
plunge down until all the liquid is
expelled.
14. If more of the purged chemical
is needed, quickly reinsert the
syringe into the
purged solution and draw out more
chemical.
15. Chemicals must be repurged if
left for longer than 10 minutes.
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Oil Bath Operation
1. Fill crystallization dish with ~200
mL high temperature silicone oil.
2. Place dish on hot plate.
3. Put paper clip into dish, which will
act as a stir rod for the oil.
4. Clamp RTD probe in clamp on
ring stand so that it is in the oil bath
without touching the glass.
5. Press heater button on plate. Set
to desired temperature. Allow ~30
minutes to reach temperature and
stabilize.
Temperature in flask will be offset
from setting on plate by ~17 °C
lower. (i.e. set: 225 °C flask: ~208
°C)
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6. Put stir bar into reaction flask. Put
thermocouple into the flask at this
point if necessary, sealing it
between the glass and the septum.
7. Put septum onto flask to seal it.
8. Clamp reaction flask in 3-finger
clamp.
9. Lower the reaction flask into the
oil bath.
Make sure the flask is not touching
the bottom of the dish.
10. Press stirrer button on plate.
Set to desired stir speed.
11. When finished with reaction, turn
off heater and stirrer.
12. Raise clamped flask out of oil
bath and clean oil off with kimwipe
with toluene and then acetone.
13. Allow oil bath to come to room
temperature.
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Se-TOP Procedure
1. Purge Octadecene (ODE)
following the Purging Procedure
for ~15 minutes.
2. Weigh out 33 mg Se powder into
a 50 mL round bottom flash. Make
sure the flask is clean and dry.
3. Drop a small stir bar in the flask.
Cap flask with a rubber septum.

Do NOT breathe in Selenium fumes.
4. Clamp the neck of the flask in a
3-finger clamp on ring stand.
5. Set heat to 150 °C.
6. Purge the flask with N2 gas by
inserting the purge needle followed
by a venting needle. Allow to purge
for 10 minutes.
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7. Transfer 5 mL ODE into the flask
using the Syringing Procedure.
8. Lower flask into oil bath.
9. Set stir to 500 rpm.
10. Begin purging trioctylphosphine
using the Purging Procedure.
Purge for ~15 minutes.
11. Using the Syringing
Procedure, add
0.4 mL of purged TOP to the SeTOP reaction flask. The majority of
the selenium should dissolve
immediately.
12. Continue stirring at 150 °C until
the solution is completely clear. If all
the selenium does not dissolve, it
may be a sign that oxygen was
introduced into the reaction and
oxidize the TOP before the selenium
and TOP can react.
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13. Remove the solution from the oil
bath and pull out the N2 needle and
vent needle.
14. Once it has cooled, clean the
outside of the flask with toluene and
acetone. This SeTOP solution can
be stored for up to a week and
makes enough SeTOP precursor for
five QD syntheses.
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Cd-Precursor Procedure
1. Weigh out 13 mg of CdO into a
50 mL round bottom flask.
2. Put a small stir bar into the
bottom of the flask.

Cadmium Oxide is toxic. Do NOT breathe fumes.
3. Insert a thermocouple so that the
wire almost touches the bottom of
the flask.
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4. Place a rubber septum onto the
flask and fold over the edges to
firmly secure the thermocouple.

5. Clamp the flask in a 3-finger
clamp on a ring stand and begin
purging with N2 using the Purging
Procedure.
Purge for ~10 minutes.
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6. Set heat on oil bath to 242 °C
(Adjust as needed to achieve 225
°C in flask).

7. Using the Syringing Procedure, add 10 mL of purged ODE into the flask.
8. Lower the flask into the oil bath.
9. Set the stir function to 500 rpm.
10. Purge the Oleic Acid using the Purging Procedure for ~10 minutes.
11. Using the Syringing Procedure, add 0.6 mL Oleic Acid to the Cd reaction
flask.
12. Heat until solution becomes optically clear. CdO has a tendency to stick to
the walls of the flask, so the flask should be agitated occasionally to prevent
build up on walls.

The chemicals in this reaction mixture become volatile around 200°C.
Do NOT breathe fumes.
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Sample Removal

Caution:
This process requires safely handling high-temperature organic, volatile
chemicals. Two people must be present and all those present must wear
appropriate safety equipment at all times.

Prepare syringes and vials while the Cd precursor is heating.
1. Attach one metal needle tip
securely to a plastic 3 mL syringe
and one to a glass 5 mL syringe
with Luer lock.
2. Remove the caps from clean,
dry vials.
3. Once the Cd precursor
becomes optically clear, ensure
that its temperature is stable at
225 °C (adjust hot plate setting as
needed to achieve stability at 225
°C).
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4. Once stable at 225 C, quickly
inject 1 mL of room-temperature
Se-TOP precursor into the hot Cd
precursor.
Start timing when the SeTOP
precursor is injected.
A white fog will immediately form
and the solution will begin
changing color to a pale yellow.

5. Using the glass syringe,
carefully remove samples of 0.5
to 3 mL at desired time intervals.
6. Put samples into separate
vials.
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7. Cap and label the vials,
indicating quantum dot type,
date synthesized, reaction
time, and absorbance
wavelength.
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Appendix A2: ZnS COATING PROCEDURE
This procedure follows the CdSe procedure detailed in Appendix A.
The first part of this protocol contains instructions to create the ZnS precursor
solution and the second part details how to coat CdSe quantum dots with a ZnS
shell.
Chemicals


1.42 mL Diethylzinc – ZnEt2 – Solution (1.0M in Heptane)



0.22mL Hexamethyldisilathiane – (tms)2S – (synthesis grade)



5.6mL Tributylphosphine – TBP – (99% tech grade)



1mL Butanol



Toluene and Acetone for cleanup

Equipment


2 – 50mL 14/20 1-neck or 3-neck Round Bottom Flasks (RBF)



2 – 1mL Disposable Plastic Syringes



2 – 3mL Disposable Plastic Syringes



2 – Small Stir Bars



1 – Medium-Sized Beaker



Hot/Stir Plate with RTD Probe



Crystallization Dish



~ 200 mL – High Temperature Silicone Oil



Analytical Balance (accurate to 0.1 mg)



Silicone and/or Rubber Septa
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Kimwipes



Thermocouple



Borosilicate Vials



Transfer pipettes



Stopwatch



Nitrile Gloves

References


Purging procedure – Appendix A1



Syringing procedure – Appendix A1



Oil bath operation – Appendix A1
Chemical Disposal

All chemicals and equipment used during the quantum dot synthesis must be
properly disposed of. Currently there is a vessel for liquid waste and a
container for solid wastes such as needles, syringes, kimwipes, etc. which are
stored in the yellow, hazardous chemical cabinet in the nanotech lab (Bldg. 41205).
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Chemical Safety
Many of the chemicals used in this process are toxic and can be very
dangerous if improperly handled. Refer to MSDS for all chemicals prior to
performing this procedure. This procedure must be carried out in a fume hood.


Tributylphosphine – pyrophoric, toxic



Diethylzinc – pyrophoric, toxic, corrosive



Hexamethydisiliathiane – toxic

105

ZnS Precursor Solution Procedure
1. Purge Tributylphosphine (TBP)
according to the Purging Procedure
for 10 minutes.

2. Drop a stir bar into a 50mL round
bottom flask.

3. Cap flask with a septum.
This will be the ZnS vessel.

4. Clamp the flask to the ring stand,
suspended above the stir plate.

5. Purge the flask according to
Purging Procedure for 10 minutes.

6. Transfer 5.6mL of TBP using the
Syringing Procedure into the flask.

106

7. Lower N2 needle in flask to below the level of the TBP. Turn the stirring
function on the hot plate to 400-500 rpm.

9. Purge the ZnEt2 solution using the Purging Procedure for 5 minutes.

10. Transfer 1.42 mL of ZnEt2 using the Syringing Procedure into the ZnS
vessel.

11. Continue stirring for 10 to 15 minutes to allow the chemicals to fully
dissolve in TBP.

12. Transfer the solution to a vial and cap with a septum.

13. Purge the vial with N2 for 5 to 10 minutes.

14. Pull out the N2 needle. This solution can be stored for up to one week.

If the solution turns murky or a white precipitate forms, the solution can no
longer be used for coating and should be disposed of.
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Coating Procedure

1. Heat the oil bath to 160 °C according to the Oil Bath Operation and allow it
to stabilize for at least 20 minutes. Turn the stirring function to 400 – 500 rpm
with a paperclip in the oil bath to serve as a flat stir rod.

2. Place a stir bar into a 50mL round bottom flask or a 3-necked round bottom
flask.

3. Insert a thermocouple so that the
wire touches the bottom of the round
bottom flask.

4. Place a septum into the neck of the
flask and fold the edges down to firmly
secure the thermocouple.

5. Clamp the flask to a ring stand and
begin purging with N2 gas using the
Purging Procedure.
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6. Select the desired CdSe quantum dot sample to be coated.

7. Using a 3 mL disposable plastic syringe, transfer the desired volume of
CdSe quantum dots into reaction flask.

The volume of CdSe dots should be between 3 mL and 10 mL. The procedure
does not scale well to volumes greater than 10 mL.

8. Lower the CdSe flask into the oil
bath and allow it to heat to 160 °C
and stabilize for 10 minutes.
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9. While the CdSe solution is
heating, purge the ZnS precursor
solution with N2 according to the
Purging Procedure.

10. Inject the desired volume of
ZnS precursor solution dropwise
over 2 minutes (according to the
concentration of CdSe QDs and
coating thickness).
11. Hold the temperature constant
at 160 °C during reaction.
12. The reaction should be allowed
to run for 10 minutes.
13. After 10 minutes, raise the flask
up out of the oil bath and allow it to
cool to 60 °C.
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14. Upon reaching 60 °C, add 1mL of butanol to avoid solidification and
flocculation.

15. When the solution reaches
room temperature, transfer the
solution to a vial using a transfer
pipette.

16. At this point, a visible change in
CdSe (left),
fluorescence should be observable
when the samples are exposed to
UV light.
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CdSe-ZnS (right)

Appendix B: Statistical Analysis of Unshelled to Shelled Quantum Dots
Paired T-Test and CI: unshelled intensity, shelled intensity
Paired T for unshelled intensity - shelled intensity

unshelled intensity
shelled intensity
Difference

N
6
6
6

Mean
1599
7788
-6189

St Dev
739
2788
2565

95% CI for mean difference: (-8881, -3497)
T-Test of mean difference = 0 (vs not = 0): T-Value = -5.91
P-Value = 0.002
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SE Mean
302
1138
1047

